Drug Interaction Report
1 drug interaction and 5 additional warnings found for the following 2 drugs:
- mibefradil
- Xospata (gilteritinib)
Drug interactions
Major drug interactions
Major:mibefradil gilteritinib
Applies to: mibefradil, Xospata (gilteritinib)
Mibefradil may significantly increase the blood levels of gilteritinib. High levels of gilteritinib can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect.
You may be more susceptible if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)
The risk and/or severity of other side effects may also increase, including:
- nausea
- vomiting
- decreased appetite
- constipation
- diarrhea
- mouth sores
- rash
- muscle and joint pain
- shortness of breath
- cough
- swelling of arms or legs
- fever
- infections
- liver or kidney problems
- inflammation of the pancreas
- low blood pressure
Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications.
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with gilteritinib.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Disease interactions
5 potential interactionsApplies to: 5 conditions, including Hypokalemia, Liver Disease, Long QT Syndrome, Renal Dysfunction, and Magnesium Imbalance.
Hypokalemia
Moderate:Xospata
The gilteritinib in Xospata has a moderate potential interaction with Hypokalemia.
Gilteritinib has been associated with prolonged cardiac ventricular repolarization (QT interval). Perform electrocardiogram (ECG) prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce the dosage of gilteritinib in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during treatment administration.
Liver Disease
Moderate:Xospata
The gilteritinib in Xospata has a moderate potential interaction with Liver Disease.
The effect of severe hepatic (Child-Pugh Class C) or severe renal impairment (Clcr = 29 mL/min) on gilteritinib pharmacokinetics is unknown.
Long QT Syndrome
Moderate:Xospata
The gilteritinib in Xospata has a moderate potential interaction with Long QT Syndrome.
Gilteritinib has been associated with prolonged cardiac ventricular repolarization (QT interval). Perform electrocardiogram (ECG) prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce the dosage of gilteritinib in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during treatment administration.
Magnesium Imbalance
Moderate:Xospata
The gilteritinib in Xospata has a moderate potential interaction with Magnesium Imbalance.
Gilteritinib has been associated with prolonged cardiac ventricular repolarization (QT interval). Perform electrocardiogram (ECG) prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce the dosage of gilteritinib in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during treatment administration.
Renal Dysfunction
Moderate:Xospata
The gilteritinib in Xospata has a moderate potential interaction with Renal Dysfunction.
The effect of severe hepatic (Child-Pugh Class C) or severe renal impairment (Clcr = 29 mL/min) on gilteritinib pharmacokinetics is unknown.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.